A Phase 2 interventional study of Nirsevimab in RSV Infection, sponsored by AstraZeneca. Completed at 28 sites in 8 countries. Open to participants aged 0 Years to 2 Years. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by AstraZeneca · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 2, and was the 13th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 0 Years to 2 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2020.
This study's enrollment of 100 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised children who are ≤ 24 months of age at the time of dose administration. Approximately 100 subjects will be enrolled. Subjects will be followed for approximately 1 year after dose administration.
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) among infants and young children, resulting in annual epidemics in Japan. Children with congenital or acquired immunodeficiencies, transplant recipients, and those receiving immunosuppressive therapy are at increased risk for severe RSV-associated LRTI with prolonged viral shedding and higher viral loads, resulting in prolonged hospitalizations, admissions to the intensive care unit (ICU), and the need for mechanical ventilation. Palivizumab (Synagis®) is the only approved agent for RSV prophylaxis, and its half-life (t1/2) is approximately 1 month, infants and young children need to receive monthly intramuscular doses of palivizumab throughout the RSV season to maintain protection. This constitutes a significant burden on healthcare providers as well as the infants/children and their families.
Nirsevimab may provide a cost-effective opportunity to protect all infants from RSV disease based on an improvement in potency and the extended t1/2 that is expected to support once-per-RSV-season dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Neonate, infant, or young child ≤ 24 months of age at the time of dose administration who, per investigator judgement, are:
The subject must meet at least 1 of the following conditions at the time of .
Exclusion Criteria:
Subject who meets any of the palivizumab indications approved in Japan other than condition.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1st RSV season: 50mg nirsevimab 1. st RSV season: 100mg nirsevimab 2. nd RSV season: 200mg nirsevimab
Drug: Nirsevimab
Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
Also known as: Nirsevimab (MEDI8897)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic Disease (NOCDs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab and within 360 days post dose. A TESAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant. AESIs were defined as AEs of immediate (type I) hypersensitivity (including anaphylaxis), thrombocytopenia, and immune complex disease following the administration of nirsevimab based on investigator assessment and Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) codes. An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature post administration of treatment.
Time frame: TEAEs were collected from the first dose administration (Day 1) up to 360 days post dose
Serum Concentrations of Nirsevimab
Serum concentrations of nirsevimab at selected time points were evaluated to confirm that adequate exposures for protection from respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) are maintained for at least 5 months after dosing.
Time frame: Baseline (Day 1) and on Days 8 (for Japanese participants), 31, 151 and 361
Number of Participants With Anti-Drug Antibody (ADA) Response to Nirsevimab
Blood samples were analyzed for the presence of ADAs for nirsevimab using validated assays.
Time frame: Baseline (Day 1) and on Days 31, 151 and 361
Number of Participants With Medically Attended (MA) RSV LRTI (Inpatient and Outpatient) and Hospitalizations
Number of participants with LRTI and hospitalizations due to reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed RSV was assessed. MA RSV LRTI consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient or outpatient setting. MA RSV LRTI with hospitalization consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient setting.
Time frame: Through 150 days post dose
This Phase 2, open-label, uncontrolled, single-dose study was conducted at 28 investigational sites in 8 countries (Belgium, Japan, Poland, South Africa, Spain, Ukraine, United Kingdom and United States) in immunocompromised children who were \<=24 months of age at the time of enrollment between 19 Aug 2020 and 17 Feb 2023.
| Milestone | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| Started | 48 | 52 |
| Completed | 45 | 49 |
| Not completed | 3 | 3 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 2 | 1 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab and within 360 days post dose. A TESAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant. AESIs were defined as AEs of immediate (type I) hypersensitivity (including anaphylaxis), thrombocytopenia, and immune complex disease following the administration of nirsevimab based on investigator assessment and Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) codes. An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature post administration of treatment.
| Participants | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| Any TEAE | 36 | 45 |
| TESAE | 12 | 20 |
| AESI based on investigator assessment | 3 | 2 |
| AESI based on selected MedDRA PT codes | 16 | 13 |
| NOCD | 0 | 0 |
Serum concentrations of nirsevimab at selected time points were evaluated to confirm that adequate exposures for protection from respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) are maintained for at least 5 months after dosing.
| mcg/mL | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| Baseline (Day 1) | NA ± NA | NA ± NA |
| Day 8 | 139.24 ± 22.26 | 206.79 ± 16.58 |
| Day 31 | 66.00 ± 141.06 | 109.77 ± 91.74 |
| Day 151 | 19.80 ± 101.19 | 24.14 ± 121.54 |
| Day 361 | 1.86 ± 119.96 | 1.93 ± 158.95 |
Blood samples were analyzed for the presence of ADAs for nirsevimab using validated assays.
| Participants | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| Day 1 | 0 | 0 |
| Day 31 | 0 | 1 |
| Day 151 | 1 | 0 |
| Day 361 | 2 | 7 |
Number of participants with LRTI and hospitalizations due to reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed RSV was assessed. MA RSV LRTI consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient or outpatient setting. MA RSV LRTI with hospitalization consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient setting.
| Participants | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| MA RSV LRTI | 0 | 0 |
| MA RSV LRTI with hospitalization | 0 | 0 |
Collected over The TEAEs were collected from the first dose administration (Day 1) up to 360 days post dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nirsevimab 50 mg/100 mg | 2/48 (4.2%) | 12/48 (25%) | 35/48 (72.9%) |
| Nirsevimab 200 mg | 1/52 (1.9%) | 20/52 (38.5%) | 41/52 (78.8%) |
| Event | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| PneumoniaInfections and infestations | 1/48 | 4/52 |
| Lower respiratory tract infectionInfections and infestations | 1/48 | 3/52 |
| COVID-19Infections and infestations | 1/48 | 3/52 |
| Rhinovirus infectionInfections and infestations | 2/48 | 0/52 |
| Viral diarrhoeaInfections and infestations | 2/48 | 0/52 |
| PyrexiaGeneral disorders | 2/48 | 1/52 |
| Candida sepsisInfections and infestations | 2/48 | 0/52 |
| Klebsiella sepsisInfections and infestations | 0/48 | 2/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/48 | 2/52 |
| Nephrotic syndromeRenal and urinary disorders | 0/48 | 2/52 |
| Event | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 18/48 | 18/52 |
| PyrexiaGeneral disorders | 13/48 | 13/52 |
| VomitingGastrointestinal disorders | 8/48 | 13/52 |
| COVID-19Infections and infestations | 4/48 | 12/52 |
| DiarrhoeaGastrointestinal disorders | 8/48 | 10/52 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 5/48 | 8/52 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 6/48 | 7/52 |
| NasopharyngitisInfections and infestations | 6/48 | 6/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/48 | 4/52 |
| Otitis mediaInfections and infestations | 5/48 | 6/52 |
The As-treated population consisted of all participants who were enrolled and received any dose of nirsevimab.
| Age, Continuous(months) | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg | Total |
|---|---|---|---|
| Mean | 7.64 ± 3.270 | 17.90 ± 3.748 | 12.97 ± 6.232 |
| Sex: Female, Male(Participants) | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg | Total |
|---|---|---|---|
| Female | 18 | 17 | 35 |
| Male | 30 | 35 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 7 |
| Not Hispanic or Latino | 44 | 49 | 93 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Nirsevimab 50 mg/100 mg | Nirsevimab 200 mg | Total |
|---|---|---|---|
| Asian | 16 | 12 | 28 |
| American Indian or Alaskan Native | 1 | 0 | 1 |
| Black or African American | 9 | 11 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 20 | 25 | 45 |
| Other | 2 | 2 | 4 |
| Multiple categories checked | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AstraZeneca (AZ) disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AstraZeneca (AZ) are accepting requests for Individual Participant Data (IPD), but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2020 to primary completion in Feb 2023, 29 months.
Results were first posted in Nov 2023, 8 months after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 29 months is above that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab
Respiratory Syncytial Virus Infections →